inbrx-106
inbrx-106: developed by 1 company · 2 clinical trials tracked.
inbrx-106 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could inbrx-106 → INBX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Inhibrx Biosciences, Inc. (INBX) Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 2/Phase 3 |
Clinical Trials (2)
A Phase II, Single-arm, Multi-center, Open-label Study of Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as an Induction Immunotherapy for Stage II/III TNBC Patients
Primary endpoint: Volumetric Response
A Phase 2/3, Randomized Study of INBRX-106 Combined With Pembrolizumab Versus Pembrolizumab as First Line Treatment for Patients With Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Expressing PD-L1 (CPS ≥20) (HexAgon-HN)
Primary endpoint: Phase 2: Objective Response Rate (ORR)
Frequently asked questions
Who is developing inbrx-106?
inbrx-106 is being developed by Inhibrx Biosciences, Inc..
How many clinical trials involve inbrx-106?
BioSniper tracks 2 clinical trials involving inbrx-106.